Byk Gulden Lomberg Chemische Fabrik Gmbh

Other

Byk Gulden Lomberg Chemische Fabrik Gesellschaft MIT Beschrankter Haftung

Byk Gulden

Kurt Klemm

Dieter Flockerzi

Wolfgang Schoetensack

Erhard Langenscheid

Wolf-Rudiger Ulrich

Wolfgang Prusse

Hermann Amschler

Erich Rapp

Horst Wolf

Uwe Kruger

Richard Schmidt

Gerhard Ludwig

Erhard Langenscheid, Deceased

Ekkehard Kraas

Sulphonyl compound

Optically pure diaryl compounds of formula I ##STR1## wherein the substituents and symbols have the meanings given int eh specification are proposed as active ingredients in medicaments for the treatment of tumors.

Diaryl compounds for their use

Diaryl compounds of formula I ##STR1## wherein Ar represents a ring of the formula ##STR2## in which Y denotes oxygen (O), sulfur (S), vinylene (--CH.dbd.CH--), azomethine (--CH.dbd.N--) or a group of the formula ##STR3## R1, R2 and R3 are identical or different and denote hydrogen, C.sub.1 -C.sub.6 -alkyl, C.sub.3 -C.sub.7 -alkoxyalkyl, aryl, aryl-C.sub.1 -C.sub.6 -alkyl or aryloxy-C.sub.1 -C.sub.6 -alkyl,

Diaryl piperidine containing esters of 1,4-dihydropyridines and coronary

The invention relates to .omega.-[2-(N-lower alkyl-benzamido)-phenyl]-alkanoic acids, their use and preparation, and medicaments containing them.

.omega.-[2-(N-Lower alkyl-benzamido)-phenyl]-alkanoic acids, their use,

A combination of urapidil and furosemide, e.g., in the form of an acid-addition salt, in the form of a physical admixture or in the form of two distinct components collectively constitutes an effective active ingredient in the treatment of hypertension. The combination is advantageously incorporated in a standard dosage form and administered by various routes to mammals afflicted with high blood pressure. By combining furosemide with urapidil on one of the noted forms, the maximum hypotensive activity of urapidil is increased, while the side effects and toxicity of urapidil are reduced.

Urapidil/furosemide compounds, compositions and use

The title compound, prepared by nitrating .beta.-D-1-(6-amino-9H-purin-9-yl)-1-deoxyribofuranuronethylamide, is physiologically active and pharmacologically acceptable. It is useful for increasing coronary blood flow and is administrable, e.g., in the form of a medicament composition.

.beta.-D-1-(6-amino-9H-purin-9-yl)-1-deoxy-2,3-di-O-nitroribofur

Aryl-substituted piperazinyl-alkylamino-uracils, the corresponding uracil ethers and uracil-thioethers and their pharmaceutically acceptable salts such as the hydrochloride, and method for the preparation of these compounds. The novel compounds are useful for lowering the blood pressure, causing an analgesic, a sedative or antihistiminic effect in mammalians.

Aryl-substituted piperazinyl-alkylamino-uracils, -uracil ethers and

Therapeutically-active and pharmacologically-acceptable N-acyl-N' -(3-amino-2-cyanoacryloyl)-formamidrazones and their pharmaceutically-acceptable acid-addition salts inhibit xanthine oxidase and are useful as the active ingredient in medicaments for the treatment of gout.

Substituted N-acyl-N'-(3-amino-2-cyanoacryloyl-)formamidrazones

Therapeutically-active and pharmacologically-acceptable 1-amido-5-cyano-4(1H)-pyrimidinones and their pharmaceutically-acceptable acid addition salts inhibit xanthineoxidase and are useful as the active ingredient in medicaments for the treatment of gout. Such pyrimidinones are prepared by treating 2-(acyl) hydrazonomethyl-3-chloro or hydroxy-4-aza-2,4-pentadienenitriles with acid.

4(1H)-pyrimidinones

Substituted hydrazino- and pyrazolo-aldopentoses and aldohexoses, which are useful as intermediates for preparing compounds, as compounds which lower the uric acid level in the blood, and as bactericides, are provided. The substituted hydrazino compounds also enter into chemical reactions which are not possible with their unsubstituted counterparts.

Derivatives of hydrazino-monosaccharides and aldohexoses which are

Aryl-substituted piperazinylalkyl-quniazolone-(4) derivatives suitable for se as hypotensive, antihistaminic, and analgesic drugs are described. Process for the preparation of the compounds by (1) intra molecular condensation of the product obtained from the reaction of a halogen carboxylanilide with an aryl piperazine; (2) reaction of an .omega.-halogen-alkyl quinazolone with an aryl piperazine; or (3), reaction of an anthranilic acid with a (4-aryl-piperazinyl-(1) carboxylamide, nitride, amidine, or iminoester, followed by alkylation of the product are also described. Pharmaceutical compositions containing the compounds and halogenalkanoic acid-6-carbamyl anilides useful for preparing the compounds are disclosed.

Therapeutic piperazinylalkyl-quinazolone-(4)-derivatives

Aryl-substituted piperazinyl-alkylamino-uracils, the corresponding uracil ethers and uracil-thioethers and their pharmaceutically acceptable salts such as the hydrochloride, and method for the preparation of these compounds. The novel compounds are useful for lowering the blood pressure in mammalians.

Insecticidal, fungicidal and bactericidal substituted formylazapentadienenitriles are prepared by hydrolyzing an azapentadienylidene ammonium salt of the formula ##EQU1##

Growing community of inventors

Allensbach, Germany

Kurt Klemm